Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
    • Semiconductors
  • Disclosures
    • Semiconductors
    • Energy
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form
  • [Disclosure] Hanwha Aerospace (012450) – Trading Suspension and Resumption of Stock Futures and Options / 2024-08-22 Disclosures
  • [Disclosure] PSK Holdings (031980) – Value-up Plan (Voluntary Filing) / 2025-04-30 Semiconductors
  • [Disclosure] Hanwha Systems (272210) – Decision on Acquisition of Shares and Investment Certificates in Other Corporations / 2025-11-24 Disclosures
  • [Disclosure] Daeduck Electronics (353200) – Decision on Record Date for Cash/In-Kind Dividend / 2025-02-20 Semiconductors
  • [Disclosure] Celltrion (068270) – Results of Annual General Meeting of Shareholders / 2025-03-25 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Status of Compliance Program (CP) Operations / 2025-07-24 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Decision on Cash and In-Kind Dividend / 2024-04-25 Disclosures
  • [Disclosure] Celltrion (068270) – Expiration of Part 1 Approval for Phase 3 Clinical Trial Plan of CT-P13 SC (Remsima Subcutaneous) in Europe Due to Development Strategy Change (Pediatric Ulcerative Colitis) / 2026-06-18 Bio & Healthcare

[Disclosure] Hanwha Aerospace (012450) – Decision on Cash Dividends / 2025-02-24

Posted on February 24, 2025August 10, 2026 By K-STOCK Editor

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Hanwha Aerospace has disclosed a decision to pay a year-end cash dividend of KRW 3,500 per common share, totaling approximately KRW 159.1B for FY2024.

📊 [Key Disclosure Contents & Major Financial Figures]

1. Dividend Details & Key Figures

  • Dividend Category / Type: Year-end Dividend / Cash Dividend
  • Dividend per Common Share: KRW 3,500
  • Dividend Yield: 1.1% (Common Shares)
  • Total Dividend Amount: KRW 159,132,918,000 (KRW 159.13B)
  • Differential Dividend Status: Not Applicable

2. Record Date and AGM Schedule

  • Record Date: December 31, 2024
  • Scheduled AGM Date: March 25, 2025
  • Board Resolution Date: February 24, 2025 (4 Outside Directors attended)
  • Expected Payment Date: Within one month following AGM approval pursuant to Article 464-2 of the Commercial Code

3. Other Key Points

  • The total dividend amount was calculated based on 45,466,548 eligible shares, excluding 114,613 treasury shares held by the company.
  • Dividend yield represents the ratio of dividend per share to the arithmetic average closing price over the one-week period preceding two trading days prior to the record date.
  • The dividend proposal is subject to change based on the audit results and final approval at the Annual General Meeting of Shareholders.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of AGM Approval and Dividend Disbursement

This filing outlines the company’s proposed year-end cash dividend of KRW 3,500 per share for FY2024. Tracking the approval of the dividend proposal at the Annual General Meeting of Shareholders scheduled for March 25, 2025, and verifying the execution of payment within one month of approval is important for confirming the completion of the shareholder return process. Finalized details can be verified in future disclosures regarding AGM results and under the ‘Matters Related to Dividends’ section in upcoming periodic reports.

📢 Disclaimer and Source Notice

Source: This content was newly generated and structured based on official data filed with the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Inquiries: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Defense

Post navigation

Previous Post: [Disclosure] Jeju Semiconductor (080220) – (Correction) Decision on Issuance of Convertible Bonds (8th Series) / 2025-02-24
Next Post: [Disclosure] Hanwha Aerospace (012450) – Decision on General Meeting of Shareholders / 2025-02-24

Related Posts

  • [Disclosure] Samsung Electronics (005930) – Other Management Matters (Voluntary Disclosure) / 2025-10-30 Semiconductors
  • [Disclosure] Celltrion (068270) – Treasury Share Acquisition Decision / 2024-06-14 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – Other Major Management Matters (Voluntary Disclosure) / 2024-11-21 Disclosures
  • [Disclosure] SK Square (402340) – Results of Annual General Meeting of Shareholders / 2025-03-27 Semiconductors
  • [Disclosure] Celltrion (068270) – CT-P13 SC (Zymfentra) Europe Phase 3 Clinical Trial Plan Application (Part 1 & 2) (Rheumatoid Arthritis Patients) / 2026-07-24 Disclosures
  • [Disclosure] Samsung Electronics (005930) – Decision on Disposal of Treasury Stock / 2026-03-18 Semiconductors
  • [Disclosure] ISU PETASYS (007660) – Decision on Acquisition of Shares and Equity Securities of Other Corporation (Voluntary Disclosure) / 2025-03-06 Semiconductors
  • [Disclosure] Samsung Electronics (005930) – Investor Relations (IR) Holding Announcement / 2024-04-05 Semiconductors
  • [Disclosure] Jusung Engineering (036930) – Change of Chief Executive Officer (CEO) / 2025-09-19 Semiconductors
  • [Disclosure] Hyundai Motor (005380) – Notice of Ex-Dividend Reference Price (Hyundai Motor Preferred) / 2024-02-27 Disclosures
  • [Disclosure] Hanwha Aerospace (012450) – (Correction) Closure of Shareholder Register or Record Date Setting / 2025-04-30 Disclosures
  • [Disclosure] KEPCO (015760 / KEP) – Submission of Audit Report / 2024-03-11 Disclosures
  • [Disclosure] Celltrion (068270) – Application for Amendment of Phase 3 Clinical Trial Plan for CT-P55 (Cosentyx Biosimilar) in the US / 2026-03-12 Disclosures
  • [Disclosure] Celltrion (068270) – Application for Phase 3 Clinical Trial Plan for CT-P13 SC in South Korea (Pediatric Ulcerative Colitis) / 2024-09-30 Disclosures

Copyright © 2026 K-Stock Briefing.

Powered by PressBook News Dark theme